397 related articles for article (PubMed ID: 19601577)
1. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
Yu Y; Kalinowski DS; Kovacevic Z; Siafakas AR; Jansson PJ; Stefani C; Lovejoy DB; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2009 Sep; 52(17):5271-94. PubMed ID: 19601577
[No Abstract] [Full Text] [Related]
2. Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
Serda M; Kalinowski DS; Mrozek-Wilczkiewicz A; Musiol R; Szurko A; Ratuszna A; Pantarat N; Kovacevic Z; Merlot AM; Richardson DR; Polanski J
Bioorg Med Chem Lett; 2012 Sep; 22(17):5527-31. PubMed ID: 22858101
[TBL] [Abstract][Full Text] [Related]
3. Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor.
Preidecker PJ; Agrawal KC; Sartorelli AC; Moore EC
Mol Pharmacol; 1980 Nov; 18(3):507-12. PubMed ID: 7007866
[No Abstract] [Full Text] [Related]
4. Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.
Opletalová V; Kalinowski DS; Vejsová M; Kunes J; Pour M; Jampílek J; Buchta V; Richardson DR
Chem Res Toxicol; 2008 Sep; 21(9):1878-89. PubMed ID: 18698850
[TBL] [Abstract][Full Text] [Related]
5. Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins.
Hodges YK; Antholine WE; Horwitz LD
Biochem Biophys Res Commun; 2004 Mar; 315(3):595-8. PubMed ID: 14975742
[TBL] [Abstract][Full Text] [Related]
6. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
Richardson DR; Kalinowski DS; Richardson V; Sharpe PC; Lovejoy DB; Islam M; Bernhardt PV
J Med Chem; 2009 Mar; 52(5):1459-70. PubMed ID: 19216562
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy.
Cory JG; Sato A; Lasater L
Adv Enzyme Regul; 1980; 19():139-50. PubMed ID: 7039256
[No Abstract] [Full Text] [Related]
8. Alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone inhibitors of ribonucleoside diphosphate reductase.
Booth BA; Agrawal KC; Moore EC; Sartorelli AC
Cancer Res; 1974 Jun; 34(6):1308-14. PubMed ID: 4363653
[No Abstract] [Full Text] [Related]
9. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
10. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Yu Y; Suryo Rahmanto Y; Hawkins CL; Richardson DR
Mol Pharmacol; 2011 Jun; 79(6):921-31. PubMed ID: 21389104
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
Krishnan K; Prathiba K; Jayaprakash V; Basu A; Mishra N; Zhou B; Hu S; Yen Y
Bioorg Med Chem Lett; 2008 Dec; 18(23):6248-50. PubMed ID: 18976907
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Kalinowski DS; Yu Y; Sharpe PC; Islam M; Liao YT; Lovejoy DB; Kumar N; Bernhardt PV; Richardson DR
J Med Chem; 2007 Jul; 50(15):3716-29. PubMed ID: 17602603
[TBL] [Abstract][Full Text] [Related]
13. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.
Lovejoy DB; Richardson DR
Blood; 2002 Jul; 100(2):666-76. PubMed ID: 12091363
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleotide reductase inhibitors as anti-herpes agents.
Wnuk SF; Robins MJ
Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
[TBL] [Abstract][Full Text] [Related]
15. Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators.
Akam EA; Chang TM; Astashkin AV; Tomat E
Metallomics; 2014 Oct; 6(10):1905-12. PubMed ID: 25100578
[TBL] [Abstract][Full Text] [Related]
16. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
Nocentini G; Federici F; Franchetti P; Barzi A
Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status.
Tian J; Peehl DM; Zheng W; Knox SJ
Cancer Lett; 2010 Dec; 298(2):231-7. PubMed ID: 20678860
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.
Popović-Bijelić A; Kowol CR; Lind ME; Luo J; Himo F; Enyedy EA; Arion VB; Gräslund A
J Inorg Biochem; 2011 Nov; 105(11):1422-31. PubMed ID: 21955844
[TBL] [Abstract][Full Text] [Related]
19. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
Bernhardt PV; Sharpe PC; Islam M; Lovejoy DB; Kalinowski DS; Richardson DR
J Med Chem; 2009 Jan; 52(2):407-15. PubMed ID: 19090766
[TBL] [Abstract][Full Text] [Related]
20. Trypanotoxic activity of thiosemicarbazone iron chelators.
Ellis S; Sexton DW; Steverding D
Exp Parasitol; 2015 Mar; 150():7-12. PubMed ID: 25595343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
